Needham analyst Serge Belanger initiated coverage of Ocular Therapeutix (OCUL) with a Buy rating and $15 price target citing Axpaxli’s potential as a “paradigm-changing wAMD treatment.” Axpaxli stands out among extended-duration development candidates due to longer duration and a unique Phase 3 program that includes a superiority trial and a non-inferiority study, the analyst tells investors. The firm believes Axpaxli has blockbuster sales potential as a maintenance regimen that improves current “treat and extend” treatment practices, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix: Strategic Developments and Revenue Growth Justify Buy Rating
- Ocular Therapeutix price target lowered to $19 at Citizens JMP, buy on weakness
- Ocular Therapeutix Inc. Faces Operational Risks Amid Regulatory Delays and Government Disruptions
- Ocular Therapeutix Reports 2024 Financial Results and Progress
- Ocular Therapeutix Earnings Call Highlights Progress and Challenges
Questions or Comments about the article? Write to editor@tipranks.com